Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-12-15 Capital/Financing Update
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
Offering document - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed offering document for a financing placement by Revive Therapeutics Ltd., describing the terms of a securities offering, including the number of units, pricing, use of proceeds, regulatory disclaimers, and risk factors. It references Canadian securities regulations (Regulation 45-106) and includes detailed information about the financing terms and the company's business activities. This is a capital raising document, not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The document is clearly about a financing update and capital raising activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-12-15 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a private placement offering of up to $5 million by Revive Therapeutics Ltd. It details the terms of the offering, including the price per unit, the composition of each unit (common share plus warrant), the use of proceeds, and the conditions for closing. It also includes disclaimers and forward-looking statements typical of financing announcements. There are no financial statements, management discussion, or detailed financial data presented. The document is not an annual or interim report, nor is it a regulatory filing or certification. It clearly relates to a capital raising activity, specifically a private placement offering. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (6745 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2022-11-30 English
Offering document - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'OFFERING DOCUMENT UNDER THE LISTED ISSUER FINANCING EXEMPTION' and details an offering of units consisting of common shares and warrants, including pricing, minimum and maximum amounts, closing date, and exchange listing information. It also contains forward-looking statements and a summary description of the business, including recent developments and clinical trials. The content focuses on a financing offering and capital raising activity rather than financial results, management changes, or regulatory filings unrelated to financing. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is clearly an offering document related to capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-11-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CEO of Revive Therapeutics Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3026 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-11-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document is primarily a certification letter and does not contain the actual interim financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is 3032 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-11-26 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management’s Discussion and Analysis – Quarterly Highlights for the three months ended September 30, 2022' and is dated November 25, 2022. It explicitly states it is an Interim MD&A prepared in compliance with Form 51-102F1 and National Instrument 51-102, which are Canadian continuous disclosure obligations. The document contains detailed discussion of business operations, liquidity, capital resources, forward-looking statements, and risk factors for the quarter ended September 30, 2022. It references unaudited condensed interim consolidated financial statements for the same period, indicating substantive financial data is included or discussed. The length of the document (15,000 characters) and the detailed content confirm it is a comprehensive interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2022-11-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.